COVID-19 pandemic is a serious concern in the new era. Acute respiratory distress syndrome (ARDS), and lung failure are the main lung diseases in COVID-19 patients. Even though COVID-19 vaccinations are available now, there is still an urgent need to find potential treatments to ease the effects of COVID-19 on already sick patients. Multiple experimental drugs have been approved by the FDA with unknown efficacy and possible adverse effects. Probably the increasing number of studies worldwide examining the potential COVID-19 related therapies will help to identification of effective ARDS treatment. In this review article, we first provide a summary on immunopathology of ARDS next we will give an overview of management of patients with COVID-19 requiring intensive care unit (ICU), while focusing on the current treatment strategies being evaluated in the clinical trials in COVID-19-induced ARDS patients.
CITATION STYLE
Aslan, A., Aslan, C., Zolbanin, N. M., & Jafari, R. (2021). Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management. Pneumonia, 13(1). https://doi.org/10.1186/s41479-021-00092-9
Mendeley helps you to discover research relevant for your work.